Portage Biotech Inc (PRTG) AI Stock Analysis

• Market Cap: $4.67M
• Dividend Yield: N/A
• Average Volume (3M): 88.98K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.00
• Revenue Growth: N/A
• EPS Growth: 48.91%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -65.69
• Shares Outstanding: 1,121,059
• 10 Day Avg. Volume: 17,257
• 30 Day Avg. Volume: 88,977
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Portage Biotech Inc. struggles with significant financial challenges, notably no revenue generation and persistent losses, which severely impact its financial performance score. Although the stock shows some positive short-term momentum, it lacks long-term upward trends. Valuation metrics are also concerning due to a negative P/E ratio. Overall, the company's financial instability and valuation concerns result in a low stock score.

Portage Biotech Inc Business Overview & Revenue Model

Company Description

Portage Biotech Inc. (PRTG) is a biotechnology company focused on developing innovative immuno-oncology therapies. The company operates primarily in the health care sector, specifically targeting the treatment of cancer through its proprietary platform technologies and a robust pipeline of novel therapeutics. Portage Biotech aims to enhance the body's immune response to fight cancer, offering potential breakthroughs in cancer treatment.

How the Company Makes Money

Portage Biotech Inc. generates revenue primarily through the development and commercialization of its proprietary cancer immunotherapy products. The company's revenue streams include licensing agreements, strategic partnerships, and collaborations with pharmaceutical companies. These partnerships often involve milestone payments, royalties on sales, and joint development efforts that leverage Portage's innovative technologies. Additionally, the company may receive funding from grants and research collaborations that support the advancement of its therapeutic pipeline. Portage's focus on cutting-edge oncology solutions positions it to capitalize on the growing demand for effective cancer treatments, contributing to its financial performance.

Portage Biotech Inc Financial Statement Overview

Summary

Portage Biotech Inc. faces significant financial challenges, with no revenue generation, persistent losses, and negative cash flows. Although the company maintains low leverage, its declining equity and asset base raise concerns about long-term sustainability.

Income Statement

Portage Biotech Inc. has reported zero revenue over the periods, indicating no sales activity. The company consistently incurs high net losses, resulting in negative net profit margins. EBIT and EBITDA margins are also negative, reflecting operational challenges in generating profits.

Balance Sheet

The company's debt-to-equity ratio is low, indicating minimal leverage. However, the declining stockholders' equity and total assets suggest weakening financial stability. The equity ratio remains positive but is trending downward, highlighting potential risks in asset management.

Cash Flow

Operating cash flow remains negative, highlighting inefficiencies in generating cash from core operations. Free cash flow is negative, showing continued cash outflows. There is no observable growth in free cash flow, raising concerns about liquidity.

Breakdown
TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-28.00K	-54.00K	―	0.00	0.00	0.00
	EBIT
-11.74M	-18.25M	-16.57M	-15.59M	-12.44M	-5.98M
	EBITDA
-78.04M	-18.20M	-15.78M	0.00	0.00	0.00
	Net Income Common Stockholders
-67.28M	-75.34M	-104.61M	-19.17M	-17.19M	-7.25M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
6.12M	5.03M	10.54M	23.35M	2.77M	3.22M
	Total Assets
9.37M	7.78M	99.13M	194.66M	174.86M	173.17M
	Total Debt
192.00K	47.00K	0.00	0.00	150.00K	3.66M
	Net Debt
-5.85M	-4.98M	-10.54M	-23.35M	-2.62M	509.00K
	Total Liabilities
397.00K	4.45M	23.73M	29.23M	27.26M	27.53M
	Stockholders Equity
8.98M	4.02M	76.05M	121.20M	101.45M	96.53M
Cash Flow		Free Cash Flow
-9.79M	-14.30M	-12.08M	-6.76M	-3.28M	-3.71M
	Operating Cash Flow
-9.79M	-14.30M	-12.07M	-6.76M	-4.28M	-3.71M
	Investing Cash Flow
2.81M	2.81M	-617.00K	0.00	-860.00K	0.00
	Financing Cash Flow
5.31M	5.97M	-117.00K	27.35M	4.76M	700.00K

Portage Biotech Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRTG, the sentiment is Negative. The current price of 4 is below the 20-day moving average (MA) of 4.51, below the 50-day MA of 4.55, and below the 200-day MA of 4.76, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 44.40 is Neutral, neither overbought nor oversold. The STOCH value of 28.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRTG.

Portage Biotech Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARQT	54 Neutral	$1.71B	―	-113.76%	―	229.74%	70.23%
OMER	49 Neutral	$407.97M	―	87.26%	―	―	-817.72%
Sector *	49 Neutral	$6.90B	-0.08	-53.01%	2.43%	24.84%	-3.06%
PRTG	45 Neutral	$4.67M	―	-194.84%	―	―	48.91%
XENE	43 Neutral	$2.62B	―	-27.85%	―	―	-10.19%
FATE	42 Neutral	$110.00M	―	-54.21%	―	-78.55%	-0.92%